Anti-Human CD47 Reference Antibody (AO-176, RUO) (HC359106)

Name: Anti-Human CD47 Reference Antibody (AO-176, RUO)
Brand: abinScience
SKU: HC359106
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HC359106
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	AO-176
Biological activity	AO-176 shows EC 50 values of 130 ng/mL (OV90), 390 ng/mL (HCC827), 649 ng/mL (SNU-1), 250 ng/mL (OV10-315), 2700 ng/mL (MDA-MB-231), 390 ng/mL (Jurkat) and 1910 ng/mL (Raji) [1]. AO-176 (10 ug/mL, 24 h) induces death of Jurkat and OV90 cells [1]. AO-176 (0.017-1000 ug/mL) binds negligibly to RBCs and does not cause agglutination of washed human RBCs [1][3]. AO-176 (10-30 ug/mL, 24 h) has no killing effect on normal cell and the activated T cells [1]. AO-176 (0.001-100 ug/mL, 90 min) directly inhibits the binding of SIRPα to CD47 on Jurkat cells with an IC 50 of 0.78 to 0.87 ug/mL [1]. AO-176 (0.01-10 ug/mL, 2 h) promotes the phagocytosis of both Jurkat, Raji, OV90, Detroit 562, and FaDu cells in a concentration-dependent manner [1][2][4]. AO-176 (1-25 mg/kg, i.v., weekly for 4 weeks) significantly suppresses the tumor growth in Raji lymphoma xenograft mice models [1]. AO-176 (10-25 mg/kg, i.p., weekly or 5 times/weeks for 5-6 weeks) significantly suppresses the tumor growth in MDA-MB-23, SNU-1 and OV90 xenograft mice models [1]. AO-176 (3-25 mg/kg) exerts anti-tumor activity in RPMI-8226 and NCI-H929 xenografted mice models [3][4]. .
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q08722
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	AO-176, AO176, AO176
Background	Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594 2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453 3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835 4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831 5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562 6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764
References	1. Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. [HC359106] 2. Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721. [HC359106] 3. William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1): 3–4 [HC359106] 4. John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1): 1844. View More [HC359106]
Note	For research use only. Not suitable for clinical or therapeutic use.